Literature DB >> 7870913

Interactions between chronic haloperidol treatment and cocaine in rats: an animal model of intermittent cocaine use in neuroleptic treated populations.

P A LeDuc1, G Mittleman.   

Abstract

This experiment investigated the possibility that rats maintained on chronic haloperidol treatment would show increased behavioral responsiveness to cocaine, similar to that observed in human stimulant abusers who are chronically treated with neuroleptics. Thus, the effects on locomotion and stereotyped behavior of intermittent injections of cocaine were investigated in female rats receiving chronic haloperidol treatment. Daily injections of haloperidol (0.2 mg/kg, IP) or vehicle were administered for 6, 12 or 18 days prior to the start of testing with cocaine and were then continued throughout cocaine testing. All rats received four doses of cocaine (0.0, 3.0, 7.5, or 15.0 mg/kg, IP) in random order with an intervening vehicle day between successive drug days. The four dose sequence of cocaine was repeated a total of four times. Initial cocaine administration produced dose dependent increases in locomotion and stereotyped behavior. When the sequence of cocaine doses was repeated, differences among treatment groups emerged. Groups treated with haloperidol exhibited heightened locomotion in response to cocaine and with repeated injections, showed a higher rate of behavioral sensitization than control animals. These differences in the behavioral response to cocaine were maintained for at least 2 months following termination of daily haloperidol treatment. In order to examine the mechanisms underlying this heightened responsiveness to cocaine, apomorphine-induced locomotion (dose range, 0-250 micrograms/kg, SC) was determined. Regardless of dose, rats treated with haloperidol showed different temporal patterns of locomotion in response to apomorphine suggesting that the increased response to cocaine was related to changes in dopaminergic receptor sensitivity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7870913     DOI: 10.1007/bf02244649

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  45 in total

1.  The demonstration of a change in adrenergic receptor sensitivity in the central nervous system of mice after withdrawal from long-term treatment with haloperidol.

Authors:  R Dunstan; D M Jackson
Journal:  Psychopharmacology (Berl)       Date:  1976-07-09       Impact factor: 4.530

2.  Long-term administration of d-amphetamine: progressive augmentation of motor activity and stereotypy.

Authors:  D S Segal; A J Mandell
Journal:  Pharmacol Biochem Behav       Date:  1974 Mar-Apr       Impact factor: 3.533

3.  Stereotyped activities produced by amphetamine in several animal species and man.

Authors:  A Randrup; I Munkvad
Journal:  Psychopharmacologia       Date:  1967

Review 4.  A psychomotor stimulant theory of addiction.

Authors:  R A Wise; M A Bozarth
Journal:  Psychol Rev       Date:  1987-10       Impact factor: 8.934

5.  The effects of dose and duration of chronic pimozide administration on dopamine receptor supersensitivity.

Authors:  K J Dewey; H C Fibiger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-05       Impact factor: 3.000

6.  The pharmacological and anatomical substrates of the amphetamine response in the rat.

Authors:  I Creese; S D Iversen
Journal:  Brain Res       Date:  1975-01-17       Impact factor: 3.252

Review 7.  Cocaine addiction: psychology and neurophysiology.

Authors:  F H Gawin
Journal:  Science       Date:  1991-03-29       Impact factor: 47.728

8.  Methylphenidate, dextroamphetamine, and levamfetamine. Effects on schizophrenic symptoms.

Authors:  D S Janowsky; J M Davis
Journal:  Arch Gen Psychiatry       Date:  1976-03

9.  Recent psychostimulant use in hospitalized schizophrenics.

Authors:  M L Richard; B I Liskow; P J Perry
Journal:  J Clin Psychiatry       Date:  1985-03       Impact factor: 4.384

10.  Pharmacological profile of dopamine receptor agonists as studied by brain dialysis in behaving rats.

Authors:  A Imperato; G Tanda; R Frau; G Di Chiara
Journal:  J Pharmacol Exp Ther       Date:  1988-04       Impact factor: 4.030

View more
  7 in total

1.  Continuous, but not intermittent, antipsychotic drug delivery intensifies the pursuit of reward cues.

Authors:  Anne-Marie Bédard; Jérôme Maheux; Daniel Lévesque; Anne-Noël Samaha
Journal:  Neuropsychopharmacology       Date:  2011-02-16       Impact factor: 7.853

2.  Repeated aripiprazole administration attenuates cocaine seeking in a rat model of relapse.

Authors:  Matthew W Feltenstein; Phong H Do; Ronald E See
Journal:  Psychopharmacology (Berl)       Date:  2009-09-25       Impact factor: 4.530

3.  The safety, tolerability, and subject-rated effects of acute intranasal cocaine administration during aripiprazole maintenance II: increased aripipirazole dose and maintenance period.

Authors:  Joshua A Lile; William W Stoops; Lon R Hays; Craig R Rush
Journal:  Am J Drug Alcohol Abuse       Date:  2008       Impact factor: 3.829

4.  Administration of ziprasidone for 10 days increases cocaine toxicity in mice.

Authors:  K Heard; S Krier; N R Zahniser
Journal:  Hum Exp Toxicol       Date:  2008-06       Impact factor: 2.903

5.  Effects of acute and chronic aripiprazole treatment on choice between cocaine self-administration and food under a concurrent schedule of reinforcement in rats.

Authors:  Morgane Thomsen; Anders Fink-Jensen; David P D Woldbye; Gitta Wörtwein; Thomas N Sager; Rene Holm; Lauren M Pepe; S Barak Caine
Journal:  Psychopharmacology (Berl)       Date:  2008-07-09       Impact factor: 4.530

Review 6.  Schizophrenia and psychostimulant abuse: a review and re-analysis of clinical evidence.

Authors:  P A LeDuc; G Mittleman
Journal:  Psychopharmacology (Berl)       Date:  1995-10       Impact factor: 4.530

7.  Haloperidol attenuates Methylphenidate and Modafinil induced behavioural sensitization and cognitive enhancement.

Authors:  Nausheen Alam; Kulsoom Choudhary
Journal:  Metab Brain Dis       Date:  2018-02-22       Impact factor: 3.584

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.